5 completed, 3 not yet recruiting, 2 active not recruiting, 2 recruiting. 14 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 5, Not yet recruiting 3, Active not recruiting 2, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Vestibular Schwannoma: new trials by email Literature Review of Vestibular Schwannoma trials Research Report on Vestibular Schwannoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Akouos, Inc. | 27 | 2025-01-17 | 2026-04-06 |
| Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Fluorescein Sodium, YELLOW560 filter - Vestibular Schwannoma | Phase 2 | Completed | Mayo Clinic | 12 | 2021-10-06 | 2023-08-01 |
| Nimodipine in Vestibular Schwanommas NiMODipine Injectable Solution, Placebo - Vestibular Schwannoma | Phase 2 | Unknown | Medical University of Vienna | 30 | 2021-05-04 | 2023-10-19 |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Recruiting | Scott R. Plotkin, MD, PhD | 109 | 2020-06-20 | 2026-10-28 |
| Study of Aspirin in Patients With Vestibular Schwannoma Aspirin, Placebo - Vestibular Schwannoma, Acoustic Neuroma | Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 97 | 2018-03-01 | 2026-10-16 |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Selumetinib - Neurofibromatosis 2, Vestibular Schwannoma | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 10 | 2017-05-08 | 2025-04-22 |
| Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Icotinib - Vestibular Schwannoma, Neurofibromatosis Type 2 | Phase 2 | Completed | Li Peng | 10 | 2016-07-01 | 2021-09-09 |
| Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Endostatin - Vestibular Schwannoma, Neurofibromatosis Type 2 | Phase 2 | Completed | Beijing Tiantan Hospital | 20 | 2014-01-01 | 2017-02-09 |
| Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Fractionated proton radiation, Losartan - Vestibular Schwannoma, Acoustic Neuroma | Phase 2 | Active not recruiting | Massachusetts General Hospital | 30 | 2011-03-08 | 2026-09-11 |
| Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) bevacizumab, laboratory biomarker analysis, quality-of-life assessment - Vestibular Schwannoma, Neurofibromatosis Type 2 | Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2010-10-01 | 2018-08-27 |
| Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Lapatinib - Neurofibromatosis 2, Vestibular Schwannoma | Phase 2 | Completed | NYU Langone Health | 21 | 2009-09-01 | 2016-03-22 |
Neuroma, Acoustic (14) · Neurofibromatosis 2 (10) · Meningioma (5) · Ependymoma (4) · Glioma (1) · Hearing Loss (1) · Neurilemmoma (1)
Cranial Nerve Diseases (14) · Cranial Nerve Neoplasms (14) · Ear Diseases (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms by Site (14) · Neoplasms, Germ Cell and Embryonal (14) · Neoplasms, Nerve Tissue (14) · Nerve Sheath Neoplasms (14) · Nervous System Diseases (14) · Nervous System Neoplasms (14) · Neuroectodermal Tumors (14) · Neuroendocrine Tumors (14) · Neuroma (14) · Otorhinolaryngologic Diseases (14)
AZD 6244 (3) · Bevacizumab (2) · Aspirin (1) · Endostatins (1) · Fluorescein (1) · Fluoresceins (1) · Lapatinib (1) · Losartan (1) · brigatinib (1) · icotinib (1) · neratinib (1)
Beijing Tiantan Hospital (4) · Akouos, Inc. (1) · Children's Hospital Medical Center, Cincinnati (1) · Li Peng (1) · Massachusetts Eye and Ear Infirmary (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Medical University of Vienna (1) · NYU Langone Health (1) · National Cancer Institute (NCI) (1) · Scott R. Plotkin, MD, PhD (1)
United States (8) · China (5) · Austria (1)
Fu Zhao (2) · Pinan Liu (2) · Aaron Tward, MD (1) · D. Bradley Welling, MD, PhD (1) · Dorian Hirschmann, MD (1) · Helen A. Shih, MD (1) · Jaishri Blakeley (1) · Karl Roessler, MD (1) · Konstantina Stankovic, MD, PhD (1) · Matthew L Carlson, MD (1) · Matthias A Karajannis, MD, MS (1) · Scott Plotkin, MD (1) · Trent Hummel, MD (1)
PMID 26976425, PMID 35229827, PMID 36240730, PMID 38904277
P30CA006973 (1)